Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

919

Enrollment

INDUSTRY

Sponsor class

Conditions

Compensated Cirrhosis
Nonalcoholic Steatohepatitis

Interventions

DRUG: Obeticholic acid (10 mg)
DRUG: Obeticholic acid (10 mg to 25 mg)
DRUG: Placebo

Sponsor

Intercept Pharmaceuticals